Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

Navigating the nocebo effect through patient engagement is the key to setting patients up for success

If you're interested in delving deeper into this topic and understanding how patient engagement can effectively navigate the nocebo effect, we invite you to explore our latest whitepaper.

OPEN Health

- PMLiVE

Medscape Medical Affairs is Advancing Equity in Clinical Trials

Clinical trials are not just a necessary step in bringing a new drug or device to market, but a crucial investment on the part of the developing company. By 2025,...

Medscape Medical Affairs

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

- PMLiVE

Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

Results showed that ABNCoV2 was not as effective against the circulating XBB.1.5 variant

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

New UK study suggests brain fog after COVID-19 is linked to blood clots

High levels of two proteins caused excess blood clotting in people with long COVID

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

Affecting approximately 1,150 people in England, Fabry disease is a rare genetic disease that can lead to progressive damage to vital organs

- PMLiVE

NHS England expands its shingles and HPV vaccination programmes

Around 900,000 more people will become eligible for a shingles vaccination

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

The secret nobody told you about how to go viral

How to create content people actually want to read and share online

Page & Page Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links